Animal experiments suggest that APOE gene deletion (APOE−/−) and the ε4 isoform may reduce the risk of RGC loss in glaucoma by inhibiting kainic acid receptor signaling, modulating microglial activation, and reducing galectin-3 expression [21,24]. This evidence concerns the gene APOE and glaucoma.